Biogen Resets Aduhelm Expectations, Expects Longer, Slower Path To Significant Sales
Best Case Scenario: Meaningful Patient Access Over Time
The company reported $1m in Q4 sales of its Alzheimer’s drug. Biogen expects Aduhelm to make a minimal contribution to full-year 2022 revenues, which will total about $1bn less than in 2021.
